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BCOR-CCNB3 positive bone sarcoma 
BCOR-CCNB3 Ewing-like tumor 
Note 
BCOR-CCNB3 Ewing-like tumors form a 
histologically heterogeneous family belonging to the 
group of small round cell tumors, just as EWS-ETS 
positive "classical" Ewing. 




Description of this new clinical entity in the literature is 
recent (Pierron et al., 2012). Clinical data of this small 
cohort of patients is under current study and only few
pieces can be displayed for now. 
Epidemiology 
BCOR-CCNB3 RT-PCR screening of a series of 
transcript-negative sarcomas yielded a total of 24 
positive cases, out of 594 (4%), meaning this entity is 
rare among the rare transcript-negative sarcomas. 
Clinics 
Clinical description is highly similar to that of  
Ewing sarcoma, with a median age of occurrence of 13 
years, a sex ratio desequilibrated towards males, and 
tumors affecting preferentially long bones, the spine 
and pelvis. 20% of patients presented with a soft tissue 
tumor. 
Pathology 
Pathological reports were consistent with an 
undifferentiated, small round cell sarcoma, suggestiv  
of the Ewing sarcoma family of tumors. However, in 
contrast to Ewing sarcoma, approximately half of the
cases lacked strong membrane positivity for CD99. 
BCOR-CCNB3-positive cases that were tested 
exhibited strong nuclear CCNB3 staining. This finding 
highlights the potential usefulness of a simple CCNB3 
immunohistochemical assay as a diagnostic test for this 
subgroup of sarcoma. 
Treatment 
Due to the recent description of this entity, 
retrospective work on received treatment is on-goin. 
Still, the treatment of these tumors is generally based 
on combined therapy with chemotherapy associated to 
best local treatment. 
Prognosis 
Retrospective work on outcome of patients harboring 
BCOR-CCNB3 positive tumors in on-going. As in all 
sarcomas, prognosis might be influenced by the 
presence of metastases at the time of diagnosis. 
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Hematoxylin and eosin staining and immunohistochemical analysis of CD99 and CCNB3 in a Ewing case as well as in two BCOR-




BCOR-CCNB3 Ewing-like tumors show a X-
chromosome paracentric inversion; the inversion 
results in fusion of the complete coding sequence of the 
BCOR gene to the last 8 exons of CCNB3, leading to a 
hybrid transcript and an oncogenic chimeric protein. 
Additional anomalies 
SNP6.0 arrays detected no alteration in 11 of the 18 
BCOR-CCNB3 Ewing-like cases studied. In the other 
seven cases, the only recurrent abnormalities were 
deletions at chromosomes 17p and 10q, each observed 
in two cases.  
Neither deletion nor amplification of the fusion 
partners was observed.  
Of note, the most frequent copy-number abnormalities 
of Ewing sarcoma, particularly the gain at chromosome 
8 that is observed in ~50% of Ewing sarcoma cases, 
and the gain of 1q or chromosome 12 or the loss of 
16q, which are each  
observed in ~25% of Ewing sarcoma cases, were not 
recurrent characteristics of BCOR-CCNB3-positive 
cases.  
These data indicate that classic Ewing sarcomas and 
BCOR-CCNB3-positive tumors do not share common 
copy-number changes. 
Genes involved and proteins 




Interacting co-repressor of BCL6. 




Cyclin B3, early meiotic cyclin in spermatogenesis. 
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A paracentric inversion on the X chromosome was seen in FISH experiments. BACs flanking BCOR were labeled with FITC, and BACs 
flanking CCNB3 were labeled with rhodamine. In control cells, (a lymphoblastoid cell line), the two red spots (or the two green spots) are 
in close proximity and appear either as a single spot or as unicolor doublets. In BCOR-CCNB3-positive cells with paracentric inversion on 
the X chromosome, the two red and green spots are split and appear as bicolored doublets. 
 
Structure of the BCOR-CCNB3 cDNA. The sequence of the BCOR-CCNB3 junction is shown, with the encoded protein sequence 
reported below it. Red dashed line and arrow indicate the fusion point. 
 




The complete coding sequence of the BCOR gene is 
fused to the last 8 exons of CCNB3, leading to a hybrid  
transcript and an oncogenic chimeric protein. The stop 
codon of BCOR (TGA) is included within a putative 
GGTGAG donor splice-site sequence. Thus, the most 
likely hypothesis accounting for the fusion mRNA is 
that this cryptic donor site is spliced with the acceptor 
site of exon 5 of CCNB3. Splicing was found to be 
incomplete, leading to both BCOR-CCNB3 and wild-
type BCOR expression. 
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Detection 
Tumors are snap frozen in liquid nitrogen. After 
crushing tumors, we isolate total RNA using the TRIzol 
reagent kit (Invitrogen). RNA is quantified with Qubit 
(Invitrogen) and Nanodrop ND1000 (ThermoFisher 
Scientific) before quality assessment with the Agilent 
2100 Bioanalyzer. Total RNAs are randomly reverse 
transcribed (Random Hexamers, Applied Biosystems, 
FosterCity, CA) with GeneAmp RNA PCR Core Kit 
(Applied Biosystems, FosterCity, CA) in three steps 
(75°C - 5'; 42°C - 30'; 85°C - 5') on a Thermomixer 
Comfort (Eppendorf, Hamburg, Germany).  
100ng of tumoral cDNA are amplified by Taq Gold 
with buffer II (Applied Biosystems, FosterCity, CA) 
with BCOR3.1. 
(5'-GGCAGGTTTCTGCAAGTCTC) and CCNB3.1. 
(5'-AGATGCCTCCTCAGTGTTGG) primers and 
sequenced by the same oligos. 
Sequence should yield a unique and tumor specific 
PCR product of 290pb. 
Fusion Protein 
Description 
The full fusion protein is expected to have a molecular 
weight of 337 kDa and to include the three known 
ankyrin domains of BCOR as well as  
 
the two known cyclin domains of CCNB3. 
Oncogenesis 
5-bromodeoxyuridine (BrdU) staining of mouse 
NIH3T3 fibroblasts overexpressing BCOR-CCNB3 or 
∆CCNB3, a truncated version of CCNB3 
corresponding to the portion involved in the fusion 
gene, was performed. Compared to the empty vector, 
both expression vectors led to a twofold increase in the 
proportion of cells in S phase. Although cell cycle 
analyses clearly show that the CCNB3 portion of the 
fusion is potentially sufficient to mediate cell cycle 
effects, it is expected that oncogenesis also relies on 
additional phenotypic effects from the full-length 
fusion protein. 
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